HER2-low breast cancer demonstrates potential differences in immune microenvironment characteristics compared to HER2-0 breast cancer, suggesting distinct mechanisms of immune regulation and infiltration (Tarantino et al., 2023b). The gene discussed is ERBB2; the disease is breast carcinoma.